An open single center single arm clinical study of t anti-BCMA CAR-T therapy for relapsed, refractory and high-risk BCMA+ tumor

Trial Profile

An open single center single arm clinical study of t anti-BCMA CAR-T therapy for relapsed, refractory and high-risk BCMA+ tumor

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Anti-BCMA-chimeric-antigen-receptor-T-cell-therapy-Wuhan-Bio-Raid-Biotechnology (Primary)
  • Indications Leukaemia; Lymphoma; Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top